未熟児網膜症治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Retinopathy Of Prematurity - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0966
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Retinopathy Of Prematurity – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity – Pipeline Review, H1 2020, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape.

Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder which usually develops in both eyes is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness Risk factors for the development of ROP include prematurity, extremely low-birth-weight, and multiple births.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Retinopathy Of Prematurity – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 9 and 1 respectively.

Retinopathy Of Prematurity (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinopathy Of Prematurity (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinopathy Of Prematurity (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinopathy Of Prematurity (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinopathy Of Prematurity (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinopathy Of Prematurity – Overview
Retinopathy Of Prematurity – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Retinopathy Of Prematurity – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinopathy Of Prematurity – Companies Involved in Therapeutics Development
Advanced Imaging Projects Inc
Anida Pharma Inc
Ayuvis Research Inc
D. Western Therapeutics Institute Inc
Everglades Biopharma LLC
Insmed Inc
Novelty Nobility Inc
Orphanix GmbH
Pamdeca LLC
Protheragen Inc
Recordati SpA
Regeneron Pharmaceuticals Inc
Signablok Inc
Retinopathy Of Prematurity – Drug Profiles
aflibercept – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVR-123 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Retinopathy of Prematurity – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mecasermin rinfabate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit SCG3 for Oncology, Ophthalmology and Diabetic Complications – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuroprotectin D1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-2901 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMD-336 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Propranolol hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Retinopathy of Prematurity – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis, Retinopathy Of Prematurity and Hemorrhagic Shock – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinopathy Of Prematurity – Dormant Projects
Retinopathy Of Prematurity – Product Development Milestones
Featured News & Press Releases
Mar 11, 2019: Bascom Palmer’s Dr. Wei Li awarded $9.12 million NEI grant
Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Retinopathy Of Prematurity, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Retinopathy Of Prematurity - Pipeline by Advanced Imaging Projects Inc, H1 2020
Retinopathy Of Prematurity - Pipeline by Anida Pharma Inc, H1 2020
Retinopathy Of Prematurity - Pipeline by Ayuvis Research Inc, H1 2020
Retinopathy Of Prematurity - Pipeline by D. Western Therapeutics Institute Inc, H1 2020
Retinopathy Of Prematurity - Pipeline by Everglades Biopharma LLC, H1 2020
Retinopathy Of Prematurity - Pipeline by Insmed Inc, H1 2020
Retinopathy Of Prematurity - Pipeline by Novelty Nobility Inc, H1 2020
Retinopathy Of Prematurity - Pipeline by Orphanix GmbH, H1 2020
Retinopathy Of Prematurity - Pipeline by Pamdeca LLC, H1 2020
Retinopathy Of Prematurity - Pipeline by Protheragen Inc, H1 2020
Retinopathy Of Prematurity - Pipeline by Recordati SpA, H1 2020
Retinopathy Of Prematurity - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Retinopathy Of Prematurity - Pipeline by Signablok Inc, H1 2020
Retinopathy Of Prematurity - Dormant Projects, H1 2020

【掲載企業】

Advanced Imaging Projects Inc
Anida Pharma Inc
Ayuvis Research Inc
D. Western Therapeutics Institute Inc
Everglades Biopharma LLC
Insmed Inc
Novelty Nobility Inc
Orphanix GmbH
Pamdeca LLC
Protheragen Inc
Recordati SpA
Regeneron Pharmaceuticals Inc
Signablok Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[未熟児網膜症治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆